HOME
CAREER NETWORK
NEWS
HOTBEDS
EVENT CENTER
CAREER FAIRS
COMPANY PROFILES
RESEARCH STORE
ABOUT US
NEWSLETTERS Free Newsletters Archive My eNewsletters NEWS News by Subject News by Disease News by Date PLoS Search News Post Your News JoVE CAREER NETWORK Job Seeker Login Most Recent Jobs Search Jobs Post Resume Career Fairs Career Resources For Employers COMMUNITY Login Become a Member Discussion Forums FAQ HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia BIOTECH WORK PORTAL Career Definitions Labor Market Reports Education & Training Regions DIVERSITY INVESTOR Market Summary News IPOs PROFILES Company Profiles START UPS Companies Events INTELLIGENCE Research Store INDUSTRY EVENTS Biotech Events Post an Event RESOURCES Real Estate Business Opportunities
<script language="javascript" src="http://at.ontargetjobs.com/addyn/3.0/701/1475036/0/681/ADTECH;loc=700;target=_blank;key=key1+key2+key3+key4;grp=[group]"></script><noscript><a href="http://at.ontargetjobs.com/adlink/3.0/701/1475036/0/681/ADTECH;loc=300;key=key1+key2+key3+key4;grp=[group]" target="_blank"><img src="http://at.ontargetjobs.com/adserv/3.0/701/1475036/0/681/ADTECH;loc=300;key=key1+key2+key3+key4;grp=[group]" border="0" width="160" height="240"></a></noscript>
VALLEY COTTAGE, N.Y., Nov. 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today the top-line results from the Bicifadine Phase 2b clinical trial for the treatment of diabetic neuropathic pain. The trial's primary objective was to compare the efficacy of two doses of Bicifadine against placebo in reducing pain associated with diabetic neuropathy. The primary endpoint of the study was the reduction in pain score during the course of treatment. The company announced that the study failed to meet its primary endpoint. The trial also failed to meet key secondary analysis.
Ron Bentsur, CEO of the company, commented: "We are all very disappointed with the results of the study. We will devote the next few days to further analyze the data and decide on the appropriate course of action for the Bicifadine program, and for the company."
CONTACT: Ron Bentsur, Chief Executive Officer of XTL BiopharmaceuticalsLtd., +1-845-267-0707 ext. 225